Asked by: Kevin McKenna (Labour - Sittingbourne and Sheppey)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of delivering universal fracture liaison services by 2030 on (a) patients and (b) the NHS; and what the annual cost to the public purse will be of delivering this.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government and NHS England support the clinical case for services which help to prevent fragility fractures and support the patients who sustain them. According to the Fracture Liaison Service Database 2022, at least 60 Trusts in England had access to a Fracture Liaison Service. This government is committed to ending the postcode lottery for access to these important preventative services, and the Department is working closely with NHS England to explore a range of options to provide better quality and access, including ways to best support local systems.
Costs and benefits will be assessed, as these options are considered, taking into consideration the evidence gathered from the 60 services already in operation in England.
Asked by: Kevin McKenna (Labour - Sittingbourne and Sheppey)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to shift care from hospitals into the community.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
It is vital to move services from hospital to community. The Chancellor made funding available for 380,000 more talking therapies for patients and put in place a £26 million capital investment scheme for mental health crisis centres. A lot of work has been done, but there is a lot more still to do.
Asked by: Kevin McKenna (Labour - Sittingbourne and Sheppey)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the £10 million allocated to the MHRA in March 2023, what progress has been made on accelerating routes for bringing innovative medical products developed onto the market.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) greatly welcomed the £10 million of funding announced by HM Treasury in March 2023, which has enabled the MHRA to make progress on the Innovative Licensing and Access Pathway (ILAP).
The ILAP harnesses the collective expertise of the regulatory and health technology assessment systems and National Health Service bodies, with the aim of supporting medicines from an early stage through to patient access more quickly. Since its launch in 2021, 166 Innovation Passports have been awarded.
The United Kingdom’s life sciences ecosystem within which the ILAP sits has evolved, with new regulatory initiatives such as the international recognition procedure. On Wednesday 6 November 2024, the ILAP partner organisations published a statement of policy intent on the relaunch of the ILAP. The new ILAP will continue to target timely patient benefit, take forward lessons learnt from the ILAP to date, and respond to the needs of our fast-paced life sciences sector by providing a more compelling offer of support to the medicine developer. The new ILAP will open to applications in March 2025, with full details of the pathway to be published in January 2025.